Valuation: MacroGenics, Inc.

Market Cap 30Cr 26Cr 24Cr 22Cr 42Cr 2.8TCr 43Cr 287.62Cr 111.41Cr 1.38TCr 111.23Cr 108.8Cr 4.79TCr P/E 2026 *
-6.95x
P/E 2027 * -3.05x
Enterprise Value 30Cr 26Cr 24Cr 22Cr 42Cr 2.8TCr 43Cr 287.62Cr 111.41Cr 1.38TCr 111.23Cr 108.8Cr 4.79TCr EV / Sales 2026 *
1.8x
EV / Sales 2027 * 3.14x
Free-Float
96.57%
Yield 2026 *
-
Yield 2027 * -
1 day-2.51%
1 week+12.83%
Current month+12.02%
1 month+2.87%
3 months+47.00%
6 months+187.65%
Current year+189.44%
1 week 4
Extreme 4
5.08
1 month 3.81
Extreme 3.81
5.08
Current year 1.58
Extreme 1.58
5.08
1 year 1.18
Extreme 1.185
5.08
3 years 0.99
Extreme 0.9897
21.88
5 years 0.99
Extreme 0.9897
29.16
10 years 0.99
Extreme 0.9897
36.48
Manager TitleAgeSince
Chief Executive Officer 53 13/08/2025
Director of Finance/CFO 59 01/05/2008
Chief Tech/Sci/R&D Officer 61 -
Director TitleAgeSince
Director/Board Member 73 01/09/2001
Director/Board Member 53 13/08/2025
Director/Board Member 62 01/10/2004
Date Insider Type Main position Quantity % Market Cap.
19/05Free

Director

25,750 0.0405%
19/05Free

Director

25,750 0.0405%
19/05Free

Director

25,750 0.0405%
Change 5-day change 1-year change 3-year change Capi.($)
-2.51%+12.83%+255.73%-18.82% 30Cr
+4.43%+2.49%+61.83%+115.25% 5.29TCr
+1.58%+14.12%+72.87%+85.18% 5.1TCr
-0.23%-0.98%-14.12%-16.00% 2.28TCr
+0.98%+9.05%-0.36%+423.40% 2.24TCr
+0.12%+7.87%+32.64%-13.76% 1.7TCr
+0.88%+5.78%+30.82%-34.26% 1.59TCr
+3.02%+12.74%+143.33%+308.04% 1.36TCr
+0.68%+2.54%+22.28%+168.03% 1.33TCr
+2.91%+8.82%+31.38% - 1.26TCr
Average +1.25%+7.70%+63.64%+113.01% 2.22TCr
Weighted average by Cap. +1.99%+6.72%+46.96%+120.45%

Financials

2026 *2027 *
Net sales 16Cr 14Cr 13Cr 12Cr 23Cr 1.55TCr 24Cr 159.63Cr 62Cr 764.66Cr 62Cr 60Cr 2.66TCr 9.43Cr 8.28Cr 7.63Cr 7.13Cr 13Cr 889.45Cr 14Cr 92Cr 35Cr 438.45Cr 35Cr 35Cr 1.52TCr
Net income -1.83Cr -1.61Cr -1.48Cr -1.39Cr -2.6Cr -172.73Cr -2.65Cr -18Cr -6.88Cr -85Cr -6.87Cr -6.72Cr -295.9Cr -13Cr -11Cr -10Cr -9.61Cr -18Cr -1.2TCr -18Cr -123.35Cr -48Cr -590.9Cr -48Cr -47Cr -2.05TCr
Net Debt - -
Logo MacroGenics, Inc.
MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its other product candidates are MGD024, retifanlimab, enoblituzumab, and vobramitamab duocarmazine. MGD024 is an investigational, next-generation, bispecific CD123 CD3 DART molecule designed to engage CD3 expressed on immune effector cells, such as T cells.
Employees
293
Date Price Change Volume
25/26/25 $4.660 -2.51% 11,25,686
24/26/24 $4.780 +1.92% 19,41,778
23/26/23 $4.690 +2.40% 14,91,011
22/26/22 $4.580 +10.90% 20,39,946
18/26/18 $4.130 +4.29% 9,73,000
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
4.660USD
Average target price
6.750USD
Spread / Average Target
+44.85%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MGNX Stock